Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Hiroki Inada

8PUBLICATIONS
24CO-AUTHORS
Disease surveillancePredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

Sort by Publication Date:
|May 06, 2026
Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

|Mar 18, 2026
Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.

Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama

|May 03, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Hiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto

|May 03, 2025
Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue

|Nov 29, 2023
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka

|Mar 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo

Pageof 2

Frequent Collaborators

7 joint publications

Yasuhito Tanaka

5 joint publications

Takayuki Tokunaga

4 joint publications

Katsuya Nagaoka

3 joint publications

Satoshi Narahara

2 joint publications

Hiroko Setoyama

2 joint publications

Takehisa Watanabe

1 joint publications

Yasuyuki Ohkawa

1 joint publications

Masao Nagasaki

1 joint publications

Yoshihiro Ogawa

1 joint publications

Atsushi Suzuki

Frequent Collaborators

7 joint publications

Yasuhito Tanaka

5 joint publications

Takayuki Tokunaga

4 joint publications

Katsuya Nagaoka

3 joint publications

Satoshi Narahara